Why APOE genotype now matters for new Alzheimer’s drugs

A new class of Alzheimer’s treatments, the anti-amyloid monoclonal antibodies lecanemab and donanemab, can modestly slow decline in early disease. For APOE4 carriers, there’s a wrinkle worth knowing about.

These drugs carry a risk of ARIA (amyloid-related imaging abnormalities: brain swelling or small bleeds seen on MRI). According to the Alzheimer’s Association, ApoE ε4 carriers may face an increased risk of ARIA, and the FDA encourages testing your ApoE ε4 status before starting treatment to inform that risk. So knowing your APOE genotype is now part of treatment decisions and safety monitoring for these therapies.

The practical upshot: these are treatments for early, confirmed disease, not a general carrier intervention, and genotype affects both eligibility and the risk-and-benefit calculation. We unpack it in the deep dive on anti-amyloid drugs and APOE4.